AGEN - Agenus Inc.
| Previous Close | 3.6700 |
| Open | 3.6600 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 1000 |
| Day's Range | 3.4600 - 3.6600 |
| 52 Week Range | 1.5400 - 6.1900 |
| Volume | 1,493,467 |
| Avg. Volume | 1,914,072 |
| Market Cap | 427.139M |
| Beta (3Y Monthly) | 2.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.39 |
| Earnings Date | Jul 28, 2017 - Jul 31, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- GlobeNewswire•14 days ago
Research Report Identifies Conagra Brands, W.R. Grace, International Flavors & Fragrances, Spirit Airlines, Sunstone Hotel Investors, and Agenus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Jan. 09, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•15 days ago
Agenus (AGEN) Surges: Stock Moves 9.4% Higher
Agenus (AGEN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
- Motley Fool•16 days ago
Why Agenus Stock Is Spiking Today
Eli Lilly's acquisition of Loxo Oncology lit a fire underneath the cancer immunotherapy company today..
- Motley Fool•17 days ago
All the Pre-JPM News Healthcare Investors Need to Know
The Super Bowl of biotech kicked off early for these companies.
- Zacks•19 days ago
Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
- Motley Fool•19 days ago
Why Celgene, Agenus, and Incyte Jumped Today
Biotech was a popular sector today. Find out why.
- Motley Fool•19 days ago
Here's Why Agenus Shares Rose as Much as 13.5% Today
The Bill & Melinda Gates Foundation helped to kick-start a vaccine manufacturing partnership for the small-cap biopharma.
- PR Newswire•20 days ago
Agenus Awarded Grant to Enable QS-21 Innovations
- Bill & Melinda Gates Foundation invests ~$1M to develop novel technology for QS-21 - Grant to develop an alternative, novel plant cell-culture based method for QS-21 production LEXINGTON, Mass. , Jan. ...
- Motley Fool•28 days ago
3 Biotech Stocks That Are Too Cheap to Ignore
These three biotech stocks could prove to be outstanding bargains for long-term investors.
- Zacks•28 days ago
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.
- Motley Fool•last month
2 Beaten-Down Biotech Stocks That Look Like Bargains Now
Market beatings for very different drugmakers may have gone too far.
- Zacks•last month
Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead
Agenus (AGEN) enters into a collaboration agreement with Gilead to develop and commercialize up to five I-O therapies.
- ACCESSWIRE•last month
Major Biotech Deals Making Sector Red Hot
HENDERSON NV / ACCESSWIRE / December 21, 2018 / Deals like the partnership between Gilead and Agenus are making the biotech industry red hot. Here are some biotech companies to look into. We are highlighting: ...
- Motley Fool•last month
Why Agenus Stock Is Soaring Today
A major development deal with Gilead Sciences sent Agenus's shares rocketing higher today.
- ACCESSWIRE•last month
4 Biotech Stocks Making Moves on Thursday December 20, 2018
CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The biotech industry has shown tremendous growth over the course of the last several months, as medical experts and professionals have sought to test ...
- MarketWatch•last month
Agenus stock shoots up 60% after announcing drug development deal with Gilead
Shares of Agenus Inc. shot up 60% in premarket trade Thursday after the company announced it was partnering with Gilead Sciences Inc. to develop up to five immuno-oncology therapies. Under the deal, Agenus will receive $150 million upon closing, including a $120 million upfront cash payment and $30 million in equities. Agenus will also receive up to about $1.7 billion in potential future fees and milestones. Gilead, whose shares ticked up 0.3% in premarket trade after the announcement, will receive exclusive rights to one of Agenus' investigational therapies and options to license two others. Gilead will also have the right of first negotiation for two additional undisclosed pre-clinical programs. Shares of Agenus have fallen 38% in the year to date, while shares of Gilead have fallen 10%. The S&P 500 has fallen 6% in the year to date.
- Reuters•last month
Gilead, Agenus sign deal to develop immuno-oncology therapies
Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies. Agenus will get an upfront cash payment of $120 ...
- PR Newswire•last month
Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies
FOSTER CITY, Calif. and LEXINGTON, Mass., Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (GILD) and Agenus Inc. (AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. Under the terms of the agreement, Agenus will receive $150 million upon closing, which includes a $120 million upfront cash payment and a $30 million equity investment. The agreement also includes approximately $1.7 billion in potential future fees and milestones. Gilead will receive worldwide exclusive rights to AGEN1423, which has an estimated IND filing by year-end 2018.
- Business Wire•last month
Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies
Gilead Sciences, Inc. (GILD) and Agenus Inc. (AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. Under the terms of the agreement, Agenus will receive $150 million upon closing, which includes a $120 million upfront cash payment and a $30 million equity investment. Gilead will receive worldwide exclusive rights to AGEN1423, which has an estimated IND filing by year-end 2018.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Amarin Corporation and Agenus
NEW YORK, NY / ACCESSWIRE / December 17, 2018 / U.S. markets slumped on Friday as bank shares dragged equities lower amidst concerns about global economic slowdown after China’s industrial and sales growth ...
- Zacks•2 months ago
Why Is Agenus (AGEN) Up 11.6% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Motley Fool•2 months agoHere's Why Agenus Stock Popped 51.6% in November
One big drugmaker's pain was this biotech's gain last month.
- GlobeNewswire•2 months ago
Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief Financial Officer (CFO). Mr. Ballantyne is an experienced financial and strategic leader in the biotech, medical device and information services industries with a proven track record of building and strengthening a company’s financial position during his career of more than 25 years. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, commented, “Over the course of his career, Evan has played key roles in successfully leading companies in the full range of strategic options in financing including private equity and public offerings.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of AGEN earnings conference call or presentation 6-Nov-18 1:30pm GMT
Q3 2018 Agenus Inc Earnings Call
- PR Newswire•2 months ago
Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell
LEXINGTON, Mass. , Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , ...
